HC Wainwright Has Negative View of Biomea Fusion Q2 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities researchers at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of Biomea Fusion in a note issued to investors on Tuesday, May 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.17) per share for the quarter, down from their prior forecast of ($0.14). The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.67) EPS and FY2028 earnings at ($0.82) EPS.

A number of other equities research analysts have also recently commented on BMEA. Citigroup started coverage on Biomea Fusion in a report on Tuesday, May 5th. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a report on Monday, April 20th. Citizens Jmp started coverage on Biomea Fusion in a report on Tuesday, May 5th. They set a “market outperform” rating and a $9.00 target price on the stock. Wall Street Zen upgraded Biomea Fusion from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, D. Boral Capital reiterated a “buy” rating and set a $12.00 target price on shares of Biomea Fusion in a report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Biomea Fusion Price Performance

BMEA opened at $1.48 on Thursday. The stock has a market cap of $107.00 million, a P/E ratio of -2.18 and a beta of -0.32. The stock’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.38. Biomea Fusion has a 1-year low of $0.87 and a 1-year high of $3.08.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.07.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Millennium Management LLC lifted its stake in shares of Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock worth $32,000 after purchasing an additional 15,675 shares during the period. ADAR1 Capital Management LLC purchased a new position in shares of Biomea Fusion during the 4th quarter worth $54,000. Jain Global LLC purchased a new position in shares of Biomea Fusion during the 4th quarter worth $68,000. Mariner LLC lifted its stake in shares of Biomea Fusion by 145.1% during the 4th quarter. Mariner LLC now owns 585,632 shares of the company’s stock worth $726,000 after purchasing an additional 346,702 shares during the period. Finally, Barclays PLC lifted its stake in shares of Biomea Fusion by 1,731.0% during the 4th quarter. Barclays PLC now owns 59,013 shares of the company’s stock worth $73,000 after purchasing an additional 55,790 shares during the period. Hedge funds and other institutional investors own 96.72% of the company’s stock.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical?stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed?lineage leukemia (MLL) protein–protein interaction.